The 2022 EASD Prospective | reduces the risk of diabetes by 61%, another finding from semaglutide

Medical pulse through the compilation and finishing, please do not reprint
without permission.

Recently, according to the information disclosure of foreign websites, a study published at the upcoming 58th Annual Meeting of the European Association for Diabetes Research (2022EASD) held in 2022 from September 19 to 23 shows that continuous semaglutide (2.
4mg/week) treatment can reduce the risk of type 2 diabetes in overweight or obese patients by more than
50%.

Can Semeglutide Reduce T2D Risk?

On June 4, 2021, the FDA approved the GLP-1 agonist semeglutide injection for chronic weight management in obese or overweight adults, and its weight loss effect is comparable to surgical treatment, in order to understand whether it can reduce the risk of type 2 diabetes (T2D), the researchers re-analyzed 2 trials (STEP1 and STEP4) on semeglutide.

In STEP1, 1961 overweight or obese participants received 2.

In STEP4, 803 overweight or obese participants were treated with semeglutide (2.

Simeglutide reduces the risk of T2D by 61% and the benefit is maintained with continued treatment

In STEP1, the 10-year risk of T2D decreased by 61% in the smeglutide-treated group (18.

And, for prediabetes or participants with normal blood glucose, the results of semeglutide risk reduction were similar
.

Among STEP4 participants, the risk score decreased the most in the first 20 weeks (20.

In summary, continuous treatment with smeglutide can significantly reduce the risk
of T2D, regardless of whether patients with prediabetes or normal blood glucose.

Source: Diabetologia.